Clinical trial · Observational
Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was closed due to investigator discretion based on the lack of ability to recruit patients and research goals of the program.
Summary
Brief summary (as posted)
Background: Allogenic hematopoietic cell transplantation (HCT) is a procedure in which a person gets stem cells from a donor in order to treat their disease. Researchers want to collect samples from people who have had or will have HCT. They will perform tests on the samples to study the immune system and its response to infections and disease. Objective: To collect biological samples from people who have had or are planning to have HCT to treat primary immunodeficiencies, blood cancers, or disorders of T-cell proliferation and/or dysregulation. Eligibility: People age 8 years and older who have undergone or are planning to undergo HCT. Design: Participants will be screened with: Medical history Medical chart review Physical exam Blood tests. Participants may give blood and urine samples. Participants may have a skin biopsy. Participants may undergo apheresis. For this, a needle will be placed into an arm vein to take blood. A machine divides the whole blood into parts. The sample cells are taken out and the rest of the blood is returned through a second needle in the other arm. Participants may have a bone marrow aspiration and biopsy. For this, the hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle. Participants may have a tumor or other abnormal tissue biopsy. For this, a tissue sample is obtained using a needle and syringe. They will sign a separate consent form. They may have a body scan or ultrasound to help locate the tumor during the biopsy. Participation lasts for as long as participants choose to give samples.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cell Transplantation | — | UNRESOLVED | — |
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | PROBABILISTIC | 0.70 |
| Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- Allogeneic HCT recipient or patient pending receipt of HCT
Primary outcomes (1)
- measure
- Sample Aquisition
- timeFrame
- Ongoing
- description
- To conduct immunological landscape studies on samples collected. To collect and bank blood, apheresis products, tumor, body fluids, and other biospecimens from patients with allogenic HCT.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
Show eligibility criteria text
* INCLUSION CRITERIA: * Diagnosis of a hematologic malignancy, immunodeficiency or disorder of T-cell proliferation and/or dysregulation * Have undergone or planning to undergo an allogenic hematopoietic cell transplantation * Age greater than or equal to 8 years * Additional inclusion criteria pertinent only for patients undergoing apheresis * Hemoglobin greater than or equal to 8 mg/dL and platelet count \> 75 K/uL * Weight greater than or equal to 48 kg * Adequate venous access EXCLUSION CRITERIA: * Active concomitant medical or psychological illnesses that may increase the risk to the subject * Inability of subject or parent/legal guardian to provide informed consent * Pregnant or breastfeeding women as some tests and procedures allowed are contraindicated in pregnancy (i.e., CT scans, administration of iodinated contrast)
References
Publications (0)
Data not yet available